

Identification of potent leads for human cAMP dependent protein kinase catalytic subunit alpha:

A strategic application of virtual screening for cancer therapeutics

Sandeep Swargam*, Dibyabhaba Pradhan and Amineni Umamaheswari**,

SVIMS Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, PIN: 517507, India.

* Presenting Author; ** Corresponding Author; Email: svims.btisnet@nic.in



Key points

- The advancement in therapeutic applications focused on specific macromolecules of deregulated cell signaling pathways bestowed novel approach to design the ligands as drug molecules against several life threatening diseases such as Cancer.
- Protein kinase A is one of the important protein in the cell signaling mechanism. cAMP, G-proteins and ATP molecules were required for activation of protein kinase A (PKA), upon activation, PKA catalytic subunits (PRKACA, PRKACB and PRKACG) undergoes many cellular functions like cell proliferations, cell cycle regulation, and survival of cells through acting on many substrates.
- Over expression of extracellular cAMP dependent protein kinase A catalytic subunits (PRKACA) causes severe tumorigenesis in different organs (prostate gland, breast, lungs and pancreas) leading to cancer.
- High throughput virtual screening was implemented herein to identify the potent leads for human PRKACA that stimulates chronic form of cancers.
- In silico* functional and phylogenetic analysis of the PRKACA protein provided enough evidences towards its cancer stimulating nature.
- Fifteen published inhibitors were taken, ligand analogues were prepared. Lead identification, lead optimization was performed and finally best lead molecules were reported based on the docking scores.

Results and discussion



Figure3. Three-dimensional structure of 2GU8 protein




Figure4. Docking of lead '1' molecule with human PRKACA and hydrogen bonding network with the residues at Thr-51, Glu-121, Val-123, Glu-127 and Thr-183, blocking the functional activity of the protein.





Figure 1. Activation of human PRKACA via G-protein and cAMP

Figure 2: Human cAMP dependent PRKACA role in cell signaling mechanism

Materials and methods

Proteomic and Pathway analysis of human PRKACA (P17612)

Retrieval of 3D-structure (2GU8) and active site determination

15 published inhibitors: H-89, Roscovitine-1, PP-2, Birb796, Mallotoxin, H-89, SB-203580, SB 202190, HA-1077, GO-6983, KN-62, Flavopiridin, Roscovitine-2, Gleevec and Ligand "796"

Ligand identification

Asinex Ltd. Subset, AKos GmbH subset, KEGG, Drug likeness NCI, Anti HIV NCI subset, UN annotated NCI subset, Chem PDB ChemBank. (one million entries)

Ligand based virtual screening

5388 Ligand analogues were generated

Generation of grid around the active site residues of protein

Filtering of 5388 conformations using LigPrep

Docking and scoring studies using Schrodinger software

Sequential application of HTVS, SP and XP docking

Selection of best lead molecules based on the dock score and interacting properties with the target protein




Figure 5. Predicted 20 best lead molecules based on the XP Gscore

- Proteomic analysis reveals that the functional properties of human cAMP dependent PRKACA.
- Pathway analysis reveals that the role of protein during signaling mechanism.
- Ligand based virtual screening was performed, and finally best 20 lead molecules were reported based on the XP Gscore.
- Lead '1' (Leptosidin) with lowest docking score. -11.02 Kcal/mol was reported as a best lead molecule to inhibit functional activity of the protein.

Conclusion

- Signal transduction mechanisms were very important in the cell survival.
- Lead1 (Leptosidin) molecule forming five hydrogen bonds at Thr-51, Glu-121, Val-123, Glu-127 and Thr-183 which were reported earlier in co-crystallographic structure.
- The twenty lead molecules reported in the present study have good binding affinity towards human cAMP dependent PRKACA. However, Leptosidin with lowest XP Gscore and good binding orientation with the important active site residues is suggested as best lead for designing potential inhibitor.

Acknowledgements

My deep sense of gratitude to the honorable Dr. A. Umamaheswari, Coordinator of BIF & Head of the Department, Bioinformatics, SVIMS, Tirupati for her guidance to carry out my project work and present the poster. I am highly thankful to DBT, ministry of science and technology, Govt. of India for providing all the necessary facilities to carryout project.